| 000 | 01118 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250514234236.0 | ||
| 264 | 0 | _c20051017 | |
| 008 | 200510s 0 0 eng d | ||
| 022 | _a1470-269X | ||
| 024 | 7 |
_a10.1038/sj.tpj.6500320 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMaring, J G | |
| 245 | 0 | 0 |
_aGenetic factors influencing pyrimidine-antagonist chemotherapy. _h[electronic resource] |
| 260 |
_bThe pharmacogenomics journal _c2005 |
||
| 300 |
_a226-43 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xmetabolism |
| 650 | 0 | 4 | _aGene Expression Regulation, Enzymologic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 650 | 0 | 4 |
_aPyrimidines _xantagonists & inhibitors |
| 700 | 1 | _aGroen, H J M | |
| 700 | 1 | _aWachters, F M | |
| 700 | 1 | _aUges, D R A | |
| 700 | 1 | _ade Vries, E G E | |
| 773 | 0 |
_tThe pharmacogenomics journal _gvol. 5 _gno. 4 _gp. 226-43 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.tpj.6500320 _zAvailable from publisher's website |
| 999 |
_c15695154 _d15695154 |
||